p16-expressing microglia and endothelial cells promote tauopathy and neurovascular abnormalities in PS19 mice
- PMID: 40381614
- PMCID: PMC12289416
- DOI: 10.1016/j.neuron.2025.04.020
p16-expressing microglia and endothelial cells promote tauopathy and neurovascular abnormalities in PS19 mice
Abstract
Cellular senescence is characterized by irreversible cell-cycle exit, a pro-inflammatory secretory phenotype, macromolecular damage, and deregulated metabolism. Senescent cells are highly associated with age-related diseases. We previously demonstrated that targeted elimination of senescent cells prevents neurodegenerative disease in tau (MAPTP301S;PS19) mutant mice. Here, we show that genetic ablation of the senescence mediator p16Ink4a is sufficient to attenuate senescence signatures in PS19 mice. Disease phenotypes-including neuroinflammation, phosphorylated tau, neurodegeneration, and cognitive impairment-were blunted in the absence of p16Ink4a. Additionally, we found that PS19 mouse brains display p16Ink4-dependent neurovascular alterations such as vessel dilation, increased vessel density, deregulated endothelial cell extracellular matrix, and astrocytic endfoot depolarization. Finally, we show that p16Ink4a deletion in endothelial cells and microglia alone attenuates many of the same phenotypes. Altogether, these results indicate that neurodegenerative disease in PS19 mice is driven, at least in part, by p16Ink4a-expressing endothelial cells and microglia.
Keywords: cellular senescence; endothelial cells; microglia; mouse model; neurodegeneration; p16(Ink4a); tauopathy.
Copyright © 2025 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests D.J.B. has a potential financial interest related to this research. He is a co-inventor on patents held by Mayo Clinic and patent applications licensed to or filed by Unity Biotechnology and is a Unity Biotechnology shareholder. Research in the Baker laboratory has been reviewed by the Mayo Clinic Conflict of Interest Review Board and is being conducted in compliance with Mayo Clinic Conflict of Interest policies.
Similar articles
-
Senolytic therapy preserves blood-brain barrier integrity and promotes microglia homeostasis in a tauopathy model.Neurobiol Dis. 2024 Nov;202:106711. doi: 10.1016/j.nbd.2024.106711. Epub 2024 Oct 21. Neurobiol Dis. 2024. PMID: 39437971 Free PMC article.
-
APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology.Mol Neurodegener. 2025 Jan 22;20(1):9. doi: 10.1186/s13024-024-00793-x. Mol Neurodegener. 2025. PMID: 39844286 Free PMC article.
-
A p16 pathway to prevention: Senescence as a driver of tau-mediated neurodegeneration.Neuron. 2025 Jul 23;113(14):2215-2217. doi: 10.1016/j.neuron.2025.06.024. Neuron. 2025. PMID: 40706558
-
Behaviour profile characterization of PS19 and rTg4510 tauopathy mouse models: A systematic review and a meta-analysis.Exp Neurol. 2025 Jul;389:115234. doi: 10.1016/j.expneurol.2025.115234. Epub 2025 Apr 2. Exp Neurol. 2025. PMID: 40185359
-
Senescence in tissue samples of humans with age-related diseases: A systematic review.Ageing Res Rev. 2021 Jul;68:101334. doi: 10.1016/j.arr.2021.101334. Epub 2021 Apr 2. Ageing Res Rev. 2021. PMID: 33819674
Cited by
-
Cerebrovascular p16INK4A expression induces cerebral small vessel disease-related phenotypes.Acta Neuropathol Commun. 2025 Aug 12;13(1):171. doi: 10.1186/s40478-025-02085-x. Acta Neuropathol Commun. 2025. PMID: 40796891 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases